Dr Phumla Sinxadi is a consultant and Senior Lecturer in the Division of Clinical Pharmacology, Department of Medicine at the University of Cape Town (UCT). She received a number of awards for her postgraduate training including the Discovery Foundation and CIDRI awards, which allowed her an opportunity to spend time at Vanderbilt University with Professor David Haas, an expert in pharmacogenomics. She won the 2013/14 South African Society for Basic and Clinical Pharmacology Best Publication (Clinical) for the paper entitled Mitochondrial Genomics and Antiretroviral Therapy-Associated Metabolic Complications in HIV-Infected Black South Africans: A Pilot Study (published in the  July 2013 issue of AIDS Res and Human Retroviruses); and the 2015 British Journal of Clinical Pharmacology Prize for the best paper published by a trainee: the paper Africa (published in the July 2015 issue of BJCP). She was the lead investigator the First-in-Man clinical trial investigating the safety, tolerability and pharmacokinetics of MMV390048, a novel antimalarial drug discovered at UCT in collaboration with Medicines for Malaria Venture and the Department of Science and Technology. In 2016, she was awarded an WHO/TDR Career Development Fellowship and spent a year at the Diseases of the Developing World unit, a Research and Development department at GlaxoSmithKline in London. Currently, her research is funded by the Medical Research Council and the National Research Foundation’s Thuthuka grants. Her main research interests include i) pharmacokinetics and pharmacogenomics of antiretroviral drugs; ii) gene-gene interactions between antiretroviral and antituberculous drugs, iii) drug development.